XML 338 R11.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment information | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment information |
Segment information | (4) Segment information Evotec’s business activities are divided into two reportable segments, whose structure reflect the internal organizational and reporting structure of the Group. In 2025, the Management Board made the decision to rename the segment previously known as “Shared R&D” to “Discovery & Preclinical Development” (D&PD) to better reflect Evotec’s strategic focus. D&PD primarily includes drug discovery and preclinical development services and solutions. Starting with sourcing novel treatment ideas derived from patient data and continuing with target validation and lead optimization. In the subsequent development phase selected candidates can seamlessly transition to IND application. Just — Evotec Biologics (JEB) is our advanced approach to discovering, optimizing, developing, and manufacturing bio-therapeutics. JEB provides services in the areas of antibody molecular optimization, product and process design, single-use disposable, perfusion-based continuous bioprocessing platforms, covering both early stage as well as commercial biomanufacturing. Management does not allocate assets and liabilities to segments. The assessment of the individual operating segments is based on revenue and operating income (loss). Inter segment revenue are valued with a price comparable to other third-party revenue. Corporate activities are allocated based on internally defined allocation keys, primarily based on revenue. The segment information for the financial year 2025 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | Discovery & | ​ ​ ​ | ​ | ​ ​ ​ | ​ | ​ ​ ​ | ​
​ | ​ ​ ​ | Preclinical | ​ ​ ​ | Just - Evotec | ​ ​ ​ | Intersegment | ​ ​ ​ | Evotec
in k€ | ​ | Development | ​ | Biologics | ​ | eliminations | ​ | Group
Revenue* |  | 528,930 |  | 259,443 |  | — |  | 788,373
Intersegment revenue | ​ | 352 | ​ | 144 | ​ | (496) | ​ | —
Cost of revenue | ​ | (482,470) | ​ | (192,161) | ​ | 479 | ​ | (674,152)
Gross profit | ​ | 46,811 | ​ | 67,426 | ​ | (17) | ​ | 114,221
Operating income and (expenses) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | (37,454) | ​ | (72) | ​ | 17 | ​ | (37,509)
Selling, general and administrative expenses | ​ | (133,248) | ​ | (42,722) | ​ | — | ​ | (175,970)
Other operating income | ​ | 61,370 | ​ | 4,230 | ​ | — | ​ | 65,599
Other operating expenses | ​ | (11,327) | ​ | (10,597) | ​ | — | ​ | (21,924)
Reorganization costs | ​ | (633) | ​ | — | ​ | — | ​ | (633)
Total operating income (expenses) | ​ | (121,294) | ​ | (49,161) | ​ | 17 | ​ | (170,438)
Operating income (loss)** |  | (74,482) |  | 18,265 |  | — |  | (56,217)
*Includes Revenue from contributions of €11,294k **Includes €65,291k of depreciation and €9,478k of amortization related to D&PD and includes €24,707k of depreciation and €-k of amortization related to JEB The segment information for the financial year 2024 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ ​ ​ | ​ | ​ ​ ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | Intersegment | ​ | Evotec
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | eliminations | ​ ​ ​ | Group
Revenue* | ​ | 611,394 |  | 185,573 |  | — |  | 796,967
Intersegment revenue |  | 160 | ​ | 1,049 | ​ | (1,208) | ​ | —
Cost of revenue | ​ | (509,361) | ​ | (173,068) | ​ | 344 | ​ | (682,086)
Gross profit | ​ | 102,192 | ​ | 13,553 | ​ | (865) | ​ | 114,881
Operating income and (expenses) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | (51,146) | ​ | (576) | ​ | 865 | ​ | (50,857)
Selling, general and administrative expenses | ​ | (158,915) | ​ | (29,286) | ​ | — | ​ | (188,201)
Other operating income | ​ | 49,802 | ​ | 2,899 | ​ | — | ​ | 52,700
Other operating expenses | ​ | (13,924) | ​ | (2,192) | ​ | — | ​ | (16,116)
Reorganization costs | ​ | (54,179) | ​ | (751) | ​ | — | ​ | (54,930)
Total operating income (expenses) | ​ | (228,362) | ​ | (29,906) | ​ | 865 | ​ | (257,403)
Operating income (loss)** | ​ | (126,170) |  | (16,353) |  | — |  | (142,522)
*Includes Revenue from contributions of €14,450k **Includes €70,753k of depreciation and €6,484k of amortization related to D&PD and includes €24,404k of depreciation and €-k of amortization related to JEB The segment information for the financial year 2023 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | Discovery & | ​ ​ ​ | ​ | ​ ​ ​ | ​ | ​ ​ ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | Intersegment | ​ | Evotec
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | eliminations | ​ ​ ​ | Group
Revenue* | ​ | 672,977 | ​ | 108,449 | ​ | — | ​ | 781,426
Intersegment revenue | ​ | — |  | — |  | — | ​ | —
Cost of revenue | ​ | (492,674) | ​ | (113,701) | ​ | — | ​ | (606,375)
Gross profit | ​ | 180,303 | ​ | (5,252) | ​ | — | ​ | 175,051
Operating income and (expenses) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | (68,529) | ​ | — | ​ | — | ​ | (68,529)
Selling, general and administrative expenses | ​ | (143,167) | ​ | (26,442) | ​ | — | ​ | (169,610)
Impairment/Reversal of impairment of intangible assets | ​ | 108 | ​ | (5,119) | ​ | — | ​ | (5,011)
Other operating income | ​ | 62,524 | ​ | 2,269 | ​ | — | ​ | 64,793
Other operating expenses | ​ | (39,361) | ​ | (4,841) | ​ | — | ​ | (44,202)
Reorganization costs | ​ | — | ​ | — | ​ | — | ​ | —
Total operating income (expenses) | ​ | (188,425) | ​ | (34,133) | ​ | — | ​ | (222,558)
Operating income (loss)** | ​ | (8,122) | ​ | (39,385) | ​ | — | ​ | (47,507)
*Includes Revenue from contributions of €9,417k **Includes €64,349k of depreciation and €6,946k of amortization related to D&PD and includes €21,685k of depreciation and €-k of amortization related to JEB - Geographical Breakdown- The geographical breakdown of revenue from customers for the financial year 2025 is stated below:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue by region |  | ​ |  | ​ |  | ​
USA |  | 323,508 |  | 108,001 |  | 431,509
Germany |  | 25,293 |  | — |  | 25,293
France |  | 19,783 |  | 72 |  | 19,855
United Kingdom |  | 61,724 |  | — |  | 61,724
Switzerland |  | 10,892 |  | 150,721 |  | 161,613
Rest of the world |  | 76,436 |  | 649 |  | 77,085
Total revenue from contracts with customers | ​ | 517,636 | ​ | 259,443 | ​ | 777,079
Revenue from contributions | ​ | 11,294 | ​ | — | ​ | 11,294
Total Revenue |  | 528,930 |  | 259,443 |  | 788,373
​ ​ The geographical breakdown of revenue from customers for the financial year 2024 is stated below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue by region |  | ​ |  | ​ |  | ​
USA |  | 354,124 |  | 91,735 |  | 445,859
Germany |  | 32,904 |  | — |  | 32,904
France |  | 19,910 |  | — |  | 19,910
United Kingdom |  | 92,437 |  | 80 |  | 92,517
Switzerland |  | 18,048 |  | 90,995 |  | 109,043
Rest of the world |  | 81,662 |  | 621 |  | 82,283
Total revenue from contracts with customers | ​ | 599,086 | ​ | 183,431 | ​ | 782,517
Revenue from contributions | ​ | 12,308 | ​ | 2,142 | ​ | 14,450
Total Revenue |  | 611,394 |  | 185,573 |  | 796,967
​ The geographical breakdown of revenue from customers for the financial year 2023 is stated below:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue by region |  | ​ |  | ​ |  | ​
USA |  | 414,192 |  | 45,232 |  | 459,424
Germany |  | 29,297 |  | 4,837 |  | 34,134
France |  | 32,005 |  | — |  | 32,005
United Kingdom |  | 86,368 |  | — |  | 86,368
Switzerland |  | 7,500 |  | 57,424 |  | 64,924
Rest of the world |  | 95,154 |  | — |  | 95,154
Total revenue from contracts with customers | ​ | 664,516 |  | 107,493 |  | 772,009
Revenue from contributions | ​ | 8,461 | ​ | 956 | ​ | 9,417
Total Revenue |  | 672,977 |  | 108,449 |  | 781,426
​ Revenue is allocated to regions according to the location of the head office of the external customer. Non-current assets categorized by the location of the companies as of December 31, 2025 and December 31, 2024 can be analyzed as follows:
​ | ​ | ​ | ​ | ​
in k€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024
USA |  | 216,421 |  | 257,861
United Kingdom |  | 180,577 |  | 208,907
Italy |  | 230,258 |  | 240,450
France |  | 89,704 |  | 325,974
Germany |  | 188,451 |  | 154,543
Total non-current assets |  | 905,411 |  | 1,187,735
​ Non-current assets shown in this table comprise of fixed assets, intangible assets, goodwill, non-current tax receivables, other non-current assets as well as investments for which the equity-method is applied. Non-current investments and deferred tax assets are not included.

X
- Definition Represent of Disclosure Of Operating Segment + References No definition available. + Details
Name: | evo_DisclosureOfOperatingSegmentAbstract
Namespace Prefix: | evo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration